Stay updated with breaking news from Preserved Ejection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - read this article along with other careers information, tips and advice on BioSpace
New data presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, held Sept. 30-Oct. 3 in Washington, DC, shed light on the impact of an FDA-cleared blood volume analysis test to benefit patients with heart failure. During the HFSA Meeting, Daxor Corporation announced new data from multiple studies validating the benefits of the company’s BVA-100 blood test for patients with heart failure.
Data extend the clinically meaningful benefits of FARXIGA in patients with heart failure regardless of ejection fraction
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaning
The pipeline of Heart failure is robust, with 100+ giant players in the pipeline, and new therapeutic strategies are being explored. ...